Top

Published in:

01-11-2007 | Original Article

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

Authors: Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon, Young Rok Do, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Keon Uk Park, Jin Ho Baek, Won Sik Lee, Joo Seop Chung, Goon Jae Cho, Chang-Hak Sohn, Jung Soon Jang, Ho Young Chung, Wansik Yu

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2007

Abstract

Purpose

Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.

Patients and methods

Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m² plus cisplatin 35 mg/m² on days 1 and 8 based on a 3-week cycle.

Results

Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no treatment-related deaths.

Conclusion

A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.

Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29PubMedCrossRef

Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Ransch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41PubMedCrossRef

Pyrhonen S, Kuitunen T, Kouri M (1995) A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Br J Cancer 71:587–591PubMed

Glimelius B, Hoffmann K, Haglund U, Nyron O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189–190PubMed

Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818PubMedCrossRef

Vanhoefer U, Wagner T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J (2001) Randomized phase II study of weekly 24-h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 37:27CrossRef

Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Hermann R, Honegger H, Cavalli F, Alberto P, Castighine M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301–306PubMedCrossRef

Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323PubMed

Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667PubMedCrossRef

10.

Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816–825PubMed

11.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef

12.

Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269–274PubMed

13.

Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L (1997) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396–399PubMedCrossRef

14.

Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempd V, Uemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458–462PubMedCrossRef

15.

Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, Park KU, Baek JH, Kim JG (2005) A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 37:349–353CrossRef

16.

Georgiadis MS, Russell EK, Gazdar AF, Johnson BE (1997) Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3:449–454PubMed

17.

Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104–1109PubMed

18.

Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T (1997) Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol 40:245–250PubMedCrossRef

19.

Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480–2486PubMedCrossRef

20.

Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361PubMed

21.

Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365–2369PubMedCrossRef

22.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan JS, Rubinstein L, Verweij J, Van Glabbeke M, Van Qosterom At, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

23.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef

24.

Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK (2004) A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 12:1059–1064PubMed

25.

Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-flourouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295–301PubMedCrossRef

26.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497–503PubMedCrossRef

Title: Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
Authors: Jong Gwang Kim
Sang Kyun Sohn
Hong Suk Song
Ki-Young Kwon
Young Rok Do
Kyung Hee Lee
Myung Soo Hyun
Hun Mo Ryoo
Sung Hwa Bae
Keon Uk Park
Jin Ho Baek
Won Sik Lee
Joo Seop Chung
Goon Jae Cho
Chang-Hak Sohn
Jung Soon Jang
Ho Young Chung
Wansik Yu
Publication date: 01-11-2007
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0433-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2007

O 4-benzylfolic acid inactivates O 6-alkylguanine-DNA alkyltransferase in brain tumor cell lines

Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma

Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model

Tumor specific cytotoxicity of glucosylceramide

Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent

Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer